カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界のアルツハイマー病用バイオマーカー市場2022年-2031年：バイオマーカー種類別（CSFバイオマーカー、遺伝子バイオマーカー、血液バイオマーカー）、検出技術別

◆英語タイトル：Alzheimer’s Disease Biomarkers Market (Type of Biomarker: CSF Biomarkers, Genetic Biomarkers, and Blood Biomarkers; and Detection Technique; Molecular Diagnostics and Immunoassays) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
	◆商品コード：TMR23JN008 ◆発行会社（リサーチ会社）：Transparency Market Research ◆発行日：2022年11月21日 ◆ページ数：180 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥869,250	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,319,250	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,769,250	見積依頼/購入/質問フォーム

★Transparency Market Researchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の市場調査レポートでは、世界のアルツハイマー病用バイオマーカー市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、種類別（CSFバイオマーカー、遺伝子バイオマーカー、血液バイオマーカー）分析、検出技術別（分子診断薬、イムノアッセイ）分析、エンドユーザー別（病院・診断所、診断研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況などの項目を掲載しています。また、企業情報として、Enzo Life Sciences, Inc.、Thermo Fisher Scientific, Inc.、AnaSpec, Inc.、Merck KGaA、Cell Signaling Technology, Inc.、Fujirebio、Imagilys、NanoSomiX、QIAGEN、23andMe, Inc.、Quanterix、C2N Diagnostics、Quest Diagnosticsなどがあります。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のアルツハイマー病用バイオマーカー市場規模：種類別
- CSFバイオマーカーの市場規模
- 遺伝子バイオマーカーの市場規模
- 血液バイオマーカーの市場規模
・世界のアルツハイマー病用バイオマーカー市場規模：検出技術別
- 分子診断薬における市場規模
- イムノアッセイにおける市場規模
・世界のアルツハイマー病用バイオマーカー市場規模：エンドユーザー別
- 病院・診断所における市場規模
- 診断研究所における市場規模
- その他エンドユーザーにおける市場規模
・世界のアルツハイマー病用バイオマーカー市場規模：地域別
- 北米のアルツハイマー病用バイオマーカー市場規模
- ヨーロッパのアルツハイマー病用バイオマーカー市場規模
- アジア太平洋のアルツハイマー病用バイオマーカー市場規模
- その他地域のアルツハイマー病用バイオマーカー市場規模
・競争状況

Alzheimer’s Disease Biomarkers Market – Scope of Report
TMR’s report on the global alzheimer’s disease biomarkers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global alzheimer’s disease biomarkers market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global alzheimer’s disease biomarkers market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the alzheimer’s disease biomarkers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global alzheimer’s disease biomarkers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global alzheimer’s disease biomarkers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global alzheimer’s disease biomarkers market.

The report delves into the competitive landscape of the global alzheimer’s disease biomarkers market. Key players operating in the global alzheimer’s disease biomarkers market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global alzheimer’s disease biomarkers market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market alzheimer’s disease biomarkers.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Alzheimer’s Disease Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Alzheimer’s Disease Biomarkers Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence and Incidence Rate globally with key countries/ region
5.4. COVID-19 Impact Analysis
6. Global Alzheimer’s Disease Biomarkers Market Analysis and Forecast, by Type of Biomarker
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Biomarker, 2017–2031
6.3.1. CSF Biomarkers
6.3.1.1. Amyloid Beta
6.3.1.2. Tau Protein
6.3.1.3. Others
6.3.2. Genetic Biomarkers
6.3.2.1. Apolipoprotein E
6.3.2.2. Others
6.3.3. Blood Biomarkers
6.4. Market Attractiveness Analysis, by Type of Biomarker
7. Global Alzheimer’s Disease Biomarkers Market Analysis and Forecast, by Detection Technique
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Detection Technique, 2017–2031
7.3.1. Molecular Diagnostics
7.3.2. Immunoassays
7.4. Market Attractiveness Analysis, by Detection Technique
8. Global Alzheimer’s Disease Biomarkers Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Laboratories
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Alzheimer’s Disease Biomarkers Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Rest of the World
9.3. Market Attractiveness Analysis, by Region
10. North America Alzheimer’s Disease Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type of Biomarker, 2017–2031
10.2.1. CSF Biomarkers
10.2.1.1. Amyloid Beta
10.2.1.2. Tau Protein
10.2.1.3. Others
10.2.2. Genetic Biomarkers
10.2.2.1. Apolipoprotein E
10.2.2.2. Others
10.2.3. Blood Biomarkers
10.3. Market Value Forecast, by Detection Technique, 2017–2031
10.3.1. Molecular Diagnostics
10.3.2. Immunoassays
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals & Clinics
10.4.2. Diagnostic Laboratories
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Biomarker
10.6.2. By Detection Technique
10.6.3. By End-user
10.6.4. By Country
11. Europe Alzheimer’s Disease Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Biomarker, 2017–2031
11.2.1. CSF Biomarkers
11.2.1.1. Amyloid Beta
11.2.1.2. Tau Protein
11.2.1.3. Others
11.2.2. Genetic Biomarkers
11.2.2.1. Apolipoprotein E
11.2.2.2. Others
11.2.3. Blood Biomarkers
11.3. Market Value Forecast, by Detection Technique, 2017–2031
11.3.1. Molecular Diagnostics
11.3.2. Immunoassays
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals & Clinics
11.4.2. Diagnostic Laboratories
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Biomarker
11.6.2. By Detection Technique
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Alzheimer’s Disease Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Biomarker, 2017–2031
12.2.1. CSF Biomarkers
12.2.1.1. Amyloid Beta
12.2.1.2. Tau Protein
12.2.1.3. Others
12.2.2. Genetic Biomarkers
12.2.2.1. Apolipoprotein E
12.2.2.2. Others
12.2.3. Blood Biomarkers
12.3. Market Value Forecast, by Detection Technique, 2017–2031
12.3.1. Molecular Diagnostics
12.3.2. Immunoassays
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals & Clinics
12.4.2. Diagnostic Laboratories
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Biomarker
12.6.2. By Detection Technique
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Rest of the World Alzheimer’s Disease Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Biomarker, 2017–2031
13.2.1. CSF Biomarkers
13.2.1.1. Amyloid Beta
13.2.1.2. Tau Protein
13.2.1.3. Others
13.2.2. Genetic Biomarkers
13.2.2.1. Apolipoprotein E
13.2.2.2. Others
13.2.3. Blood Biomarkers
13.3. Market Value Forecast, by Detection Technique, 2017–2031
13.3.1. Molecular Diagnostics
13.3.2. Immunoassays
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals & Clinics
13.4.2. Diagnostic Laboratories
13.4.3. Others
13.5. Market Attractiveness Analysis
13.5.1. By Type of Biomarker
13.5.2. By Detection Technique
13.5.3. By End-user
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Company Profiles
14.2.1. Enzo Life Sciences, Inc.
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Product Portfolio
14.2.1.3. Financial Overview
14.2.1.4. Strategic Overview
14.2.1.5. SWOT Analysis
14.2.2. Thermo Fisher Scientific, Inc.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Product Portfolio
14.2.2.3. Strategic Overview
14.2.2.4. SWOT Analysis
14.2.3. AnaSpec, Inc.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Product Portfolio
14.2.3.3. Strategic Overview
14.2.3.4. SWOT Analysis
14.2.4. Merck KGaA
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Product Portfolio
14.2.4.3. Strategic Overview
14.2.4.4. SWOT Analysis
14.2.5. Cell Signaling Technology, Inc.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Product Portfolio
14.2.5.3. Strategic Overview
14.2.5.4. SWOT Analysis
14.2.6. Fujirebio
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Product Portfolio
14.2.6.3. Strategic Overview
14.2.6.4. SWOT Analysis
14.2.7. Imagilys
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Product Portfolio
14.2.7.3. Strategic Overview
14.2.7.4. SWOT Analysis
14.2.8. NanoSomiX
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Product Portfolio
14.2.8.3. Strategic Overview
14.2.8.4. SWOT Analysis
14.2.9. QIAGEN
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Product Portfolio
14.2.9.3. Strategic Overview
14.2.9.4. SWOT Analysis
14.2.10. 23andMe, Inc.
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Product Portfolio
14.2.10.3. Strategic Overview
14.2.10.4. SWOT Analysis
14.2.11. Quanterix
14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.11.2. Product Portfolio
14.2.11.3. Strategic Overview
14.2.11.4. SWOT Analysis
14.2.12. C2N Diagnostics
14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.12.2. Product Portfolio
14.2.12.3. Strategic Overview
14.2.12.4. SWOT Analysis
14.2.13. Quest Diagnostics
14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.13.2. Product Portfolio
14.2.13.3. Strategic Overview

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のアルツハイマー病用バイオマーカー市場2022年-2031年：バイオマーカー種類別（CSFバイオマーカー、遺伝子バイオマーカー、血液バイオマーカー）、検出技術別(Alzheimer’s Disease Biomarkers Market (Type of Biomarker: CSF Biomarkers, Genetic Biomarkers, and Blood Biomarkers; and Detection Technique; Molecular Diagnostics and Immunoassays) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のアルツハイマー病用バイオマーカー市場2022年-2031年：バイオマーカー種類別（CSFバイオマーカー、遺伝子バイオマーカー、血液バイオマーカー）、検出技術別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp